L-Carnitine is a vitamin-like nutrient that is synthesized in the body, using the amino acids lysine and methionine as precursors. Because the body produces L-Carnitine on its own, it cannot be classified as a vitamin, even though it has functions similar to B vitamins. Fumarate is also a natural compound found in the body. Fumarate serves as an intermediate in the Krebs cycle, a key cellular energy-producing process. L-Carnitine and Fumarate both play important roles in energy metabolism.
Best L-Carnitine contains BIOSINT™ L-Carnitine Fumarate, which is made in
Italy by Sigma Tau Health Science. It is derived from a
base of pharmaceutical-grade L-Carnitine manufactured
using an FDA-approved process that fully complies with
international monograph standards for carnitine production. No biotechnology or genetically modified organisms are involved. L-Carnitine Fumarate is certified GMO free, BSE safe, pesticide free and Kosher. It is also ISO 9002 certified and NNFA GMP certified. L-Carnitine Fumarate is highly stable and bioavailable.
Known as a global leader in L-Carnitine research, Sigma Tau holds numerous patents for production of L-Carnitine, and its L-Carnitine derivatives are used in clinical trials. Sigma Tau Health Science has the only FDA-approved (1984) pharmaceutical batch process system for consistent L-Carnitine quality, and has been manufacturing L-Carnitine derivatives for 30 years.

Helps the
body burn fat for energy*
L-Carnitine promotes energy
production in cells by transporting fatty acids into the mitochondrion.
Its primary function is to transfer long-chain fatty acids across the
inner mitochondrial membrane. Fatty acid molecules are activated to
coenzyme A (CoA) esters in the cytoplasm of the cell, and then
esterified to L-Carnitine. The combination of a fatty acid molecule and
L-Carnitine is called "acyl-carnitine." Much of the body's L-Carnitine
content is stored in the form of acyl-carnitine.1
The mitochondrion is the cell's
energy-generating furnace. Called an "organelle," the mitochondrion is a
self-contained structure inside the cell. Like all cellular structures,
the mitochondrion is surrounded by a membrane. This membrane is an
impenetrable barrier to acyl-CoA esters; passage across the membrane
requires L-Carnitine as a transporter. On the inside of the
mitochondrial membrane, the acyl-CoA esters are made available to be
metabolized through the process of beta oxidation. One of the key
metabolic byproducts of this process is acetyl-CoA, also called "active
acetate," which enters the Krebs cycle (also known as the "citric acid
cycle") to supply fuel for production of ATP, the cell's primary energy
"currency." L-Carnitine shuttles excess fatty acid residues out of the
mitochondrion, and in this role is essential for preventing toxic
buildup of fatty acids inside the mitochondrion.
Evidence suggests that L-Carnitine
and short chain acyl-carnitine esters can protect the mitochondrion from
adverse effects of drugs and toxic chemicals. L-Carnitine has been shown
to protect animals form cardiotoxins and decrease mortality rate in
animals with diphtheria, due to this cardioprotective effect.2
Helps
maintain a healthy heart and cardiovascular system*
Muscle tissue contains a high
concentration of L-Carnitine. With its constant energy needs, heart
muscle tissue is especially rich in L-Carnitine. If the body's ability
to biosynthesize L-Carnitine is compromised, energy production in muscle
tissue is impaired, and a toxic buildup of fatty acids can occur.3
Defective production of L-Carnitine by the body can result from a
variety of factors, including kidney or liver malfunction, increased
catabolism or the inability of tissues to extract and retain L-Carnitine
from the blood.
Along with glucose and lactate,
fatty acids are the primary oxidation fuel for the heart. A considerable
amount of scientific data from animal experiments indicates that
L-Carnitine protects the heart under conditions of hypoxia, or low
oxygen. In addition to the oxidation of fat for energy in the cell,
L-Carnitine is involved in the metabolism of glucose.4 Evidence of
L-Carnitine's role in glucose metabolism was uncovered in a small trial
on 9 diabetic individuals. Given intravenously, L-Carnitine improved
insulin-mediated glucose utilization and insulin sensitivity.5
Depletion of the body's
L-Carnitine supply is linked to various abnormal states, especially of
the heart muscle. The effect of L-Carnitine on hypoxic (oxygen-starved)
isolated heart muscle tissue has been studied.6 At high concentrations,
L-Carnitine demonstrates a clear-cut ability to potentiate the
contractility of isolated heart muscle tissue, indicating the
L-Carnitine has a strengthening effect on the heart. L-Carnitine has
been shown to improve the performance of rats subjected to fatigue test.
Research has revealed that in
animals and humans with defective heart muscle, the amount of free
L-Carnitine (not bound to fatty acids) is reduced. Administration of
L-Carnitine to hamsters prevents damage to the heart muscle. Given to
humans with angina, L-Carnitine was found to improve exercise tolerance.
In a small study, patients with congestive heart failure showed gains in
heart function with oral consumption of L-Carnitine, reportedly by
restoring normal oxidation of fatty acids.7 In heart valve replacement
patients, L-Carnitine has been shown to increase the valve tissue levels
of ATP, pyruvate and creatine phosphate, which are key cellular energy
substrates. In a controlled study, L-Carnitine was administered to 38
patients prior to open heart surgery. Prior to surgery, heart
circulatory function, as assessed by measurements of hemodynamics, was
"good" in all 38. While there was evidence of a "preserving" effect of
L-Carnitine on heart cells, no differences in cardiac performance were
observed. These results suggest that noticeable improvements in heart
muscle performance with L-Carnitine are most likely to occur in people
with compromised hearts.8
It has been suggested that
L-Carnitine favorably influences blood lipids. Preliminary evidence of
this was seen in a small open trial on 26 patients who took 3 grams of
L-Carnitine daily for 40 days. Blood levels of cholesterol and
triglycerides dropped substantially, while the ratio of total to HDL
cholesterol–– a known marker of cardiovascular health––markedly
improved.9
While L-Carnitine is not a
treatment for heart disease, (nor should it be used as a substitute for
medical treatment) the results of these and other studies suggest that
oral consumption of L-Carnitine has a beneficial influence on
maintaining a healthy heart and cardiovascular system.
Suggested Adult Use: Take 1 to 4
capsules daily without food.
L-Carnitine is considered to be
very safe for oral consumption. L-Carnitine is generally well tolerated,
even at doses as high as 15 grams daily. Toxicity or overdosage has not
been reported.10
1. Wagenmakers, A. L-Carnitine supplementation and
performance in man. Brouns, F. ed. Advances in Nutrition and Top Sport.
Med Sport Sci. Basel, Karger, 1991;32:110-27.
2. Arrigoni-Martelli, E., Caso, V. Carnitine protects mitochondria and
removes toxic acyls from xenobiotics. Drugs Exptl. Clin. Res.
2001;27(1):27-49)
3. Pepine, C.J. The therapeutic potential of carnitine in cardiovascular
disorders. Clinical Therapeutics 1991;13(1):2-21.
4. Calvani, M., Reda, E., Arrigoni-Martelli, E. Regulation by carnitine
of myocardial fatty acid and carbohydrate metabolism under normal and
pathological conditions. Basic Research in Cardiology 2000;95(2):75-83.
5. Capaldo, B. et al. Carnitine improves peripheral glucose disposal in
non-insulin-dependent diabetic patients. Diabetes Research and Clinical
Practice 1991;14:191-96.
6. Fanelli, O. Carnitine and acetyl-carnitine, natural substances
endowed with interesting pharmacological properties. Life Sciences
1978;23:2563-2570.
7. Kobayashi, A., Masumura, Y., Yamazaki, N. L-Carnitine treatment for
congestive heart failure-experimental and clinical study. Japanese
Circulation Journal 1992;56:86-94.
8. Pastoris, O. et al. Effect of L-Carnitine on myocardial metabolism:
results of a balanced, placebo-controlled, double-blind study in
patients undergoing heart surgery. Pharmacological Research
1998;37(2):115-22.
9. Pola, P. et al. Carnitine in the therapy of dyslipidemic patients.
Current Therapeutic Research 1980;27(2):208-16.
10. L-Carnitine. PDR for Nutritional Supplements. First Ed.
2001.Montvale, NJ:Medical Economics.